Canaccord lowered the firm’s price target on Doximity (DOCS) to $50 from $71 and keeps a Hold rating on the shares. The firm said as expected, Doximity completed its FY’25 with a strong beat, maybe not to the degree as 3Q, but still nothing to sneeze at with revenue and adj-EBITDA upside of roughly 4% and roughly 10% versus their estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity: Strong Performance Amidst Cautious Outlook Warrants Hold Rating
- Doximity’s Strong Q4 Performance Overshadowed by Cautious FY 2026 Outlook: Hold Rating Maintained
- Doximity Hold Rating: Strong Performance Overshadowed by Policy Uncertainties and Cautious Upsell Momentum
- Cautious Outlook for Doximity Amid Strong Financials and Macroeconomic Uncertainties
- Doximity’s Strong Financial Performance and Strategic Positioning Justify Buy Rating